Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy

Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Study ID
NCT00127569
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This trial is aimed to study the efficacy of 4 weekly cycles of rituximab in HIV-infected patients with multicentric Castleman disease (giant lymph node hyperplasia) dependent on chemotherapy. Efficacy is assessed by the complete response rate at day 60. The patients are followed until day 365.

Key Dates

Start date
May 31, 2003
Status verified
Jan 2007
Completion
Jan 31, 2006

Study Design

Enrollment
25 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Sustained response rate of multicentric Castleman disease at day 60, after 4 infusions of rituximab

Related Studies